First Online: 26 October 2018
: G.L. has received research funding, honoraria and consulting fees from Affiris, Amgen, Pfizer, Regeneron and Sanofi. B.C. has received research funding from Pfizer, Regeneron and Sanofi and honoraria from Amgen, Merck Sharpe & Dohme (Merck & Co.), Regeneron and Sanofi. G.K.H.’s institution has received payment for conducting clinical trials from Aegerion, Amgen, AstraZeneca, Eli Lilly, Genzyme, Ionis Pharmaceuticals, Kowa, Pfizer, Regeneron, Roche, Sanofi and Synageva and for lectures and/or advisory panel participation from Amgen, Pfizer, Roche and Sanofi. R.M.S. declares no competing interests.